We passionately improve health

Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.

THERAPEUTIC AREA

Cardiovascular

Cardiovascular disease

including

heart disease

and stroke

is a major
global health concern and the leading cause of death and disability worldwide¹

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide¹. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

¹ Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn more

Metabolic

425

million adult people

in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases¹

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases¹. This number is projected to increase to 629 million people by 2045¹. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.

¹ Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)

Learn more

Respiratory

Boehringer Ingelheim

has over 90 years

of heritage

in managing

respiratory disease

Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life

Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Learn more

WR43747-29/01/2020
Production date: Dec 2018